Am J Cancer Res 2026;16(7):3193-3197
www.ajcr.us /ISSN:2156-6976/ajcr0172702

Erratum
HSP105 suppresses the progression of cutaneous squamous cell carcinoma by activating the P53 signaling pathway: Am J Cancer Res. 2023; 13(7): 3013-3026

Meng Jia, Kai-Yi Zhou, Li-Jia Deng, Sheng Fang

Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Received March 17, 2026; Accepted May 20, 2026; Epub July 15, 2026; Published July 30, 2026

In this article, we found that there are some errors in **Figures 1**, **4** and **5**. Therefore, we provide the correct version to replace the wrong figures and reflect changes. We sincerely apologize for this oversight and any confusion that may have caused. The corrected **Figures 1**, **4** and **5** are shown below.

Address correspondence to: Sheng Fang, Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China. E-mail: fangshengderm@163.com

https://doi.org/10.62347/YEXZ3177



Figure 1. Downregulation of HSP105 expression in cSCC cells. (A) Real-time PCR and (B) Western blot analysis of HSP105 expression in HaCaT human keratinocytes and two cSCC cell lines (A431 and SCL-1). GAPDH was used as a loading control. (C) HSP105 overexpression and knockdown vectors and their negative controls were transfected with lentiviral efficiency up to 90%. HSP105 was stably overexpressed in LV-HSP105 cells compared to untreated and LV-con cells by (D) real-time PCR and (E) Western blot analysis. Stable knockdown of HSP105 expression in sh-HSP105 cells compared to untreated and sh-con cells by (F) real-time PCR and (G) Western blotting analysis. All results are presented as the mean ± SEM using one-way ANOVA in at least three independent experiments. **P < 0.01, ***P < 0.001, ****P < 0.0001, compared to the untreated group.


A
A431
SCL-1
Untreated
LV-con
LV-HSP105
0h
24h
48h
Realtive migration
24h
48h
B
Untreated
LV-con
LV-HSP105
A431
SCL-1
Realtive invasion cells (%)
C
mRNA expression level (relative to GAPDH)
MMP9
MMP2
D
MMP-9
MMP 2
GAPDH
E
untreated
sh-con
sh-HSP105
F
G
H
MMP 9
MMP-2

Figure 4. HSP105 suppresses cSCC cell migration and invasion. (A) LV-HSP105 transfection resulted in a smaller migration area in A431 and SCL-1 cells. (B) Transwell assays showed that cell invasion was reduced after HSP105 overexpression. The results of (C) real-time PCR and (D) Western blot analysis showed reduced expression levels of MMP-2 and MMP-9 in the HSP105-overexpressing A431 and SCL-1 cells. (E) sh-HSP105 transfection resulted in a larger migration area in A431 and SCL-1 cells. (F) Enhanced cell invasion after HSP105 silencing. (G) Real-time PCR and (H) Western blot analysis showed elevated expression levels of MMP-2 and MMP-9 in A431 and SCL-1 cells with HSP105 knockdown. All results are presented as the mean ± SEM using one-way ANOVA in at least three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, compared to the untreated group.





Figure 5. HSP105 suppresses cSCC cell growth by activating the MDM2/P53 signaling pathway. (A) Real-time PCR and (B) Western blot analysis showed that MDM2 protein levels were decreased and P53 protein levels were increased in A431 and SCL-1 cells after HSP105 overexpression. Moreover, CDK4 was downregulated, while the apoptosis-related protein Bax was upregulated and Bcl2 was downregulated. (C) Real-time PCR and (D) Western blot analysis showed the opposite results when HSP105 was knocked down. Co-IP (E) results show that there is an interaction between HSP105 and P53. The expression of HSP90 and HSP70 did not change in response to the elevation or knockdown (F) of HSP105.